Overexpression of CARM1 in Breast Cancer is Correlated with Poorly Characterized Clinicopathologic Parameters and Molecular Subtypes

Overview

Journal Diagn Pathol

Publisher Biomed Central

Specialty Pathology

Date 2013 Aug 7

PMID 23915145

Citations 44

Authors

Hongxia Cheng

Yejun Qin

Hui Fan

Peng Su

Xiaofang Zhang

Hui Zhang

Gengyin Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Coactivator-associated arginine methyltransferase 1 (CARM1) belongs to the protein arginine methyltransferase family. CARM1 has been reported to be associated with high grade tumors in breast cancer. It still remains unknown the expression pattern of CARM1 in breast cancer and its relationships with clinicopathological characteristics and molecular subtypes.

Methods: Two hundred forty-seven invasive breast cancer cases were collected and prepared for tissue array. There were thirty-seven tumors with benign glandular epithelium adjacent to the tumors among these cases. Molecular subtype and CARM1 expression were investigated using immunohistochemistry.

Results: Cell staining was observed in the cytoplasm and/or nucleus. Staining for CARM1 was significantly stronger in adenocarcinoma compared with adjacent benign epithelium. There is a significant correlation between CARM1 overexpression with young age, high grade, estrogen receptor (ER) and progesterone receptor (PR) negative, increased p53 expression, and high Ki-67 index. Our study demonstrated CARM1 overexpression was associated with an increase in the protein expression of HER2. Furthermore, our data indicated CARM1-overexpression rate were remarkably higher in HER2 subtype (69.6%), luminal B subtype (59.6%) and TN subtype (57.1%) compared with luminal A subtype (41.3%).

Conclusions: CARM1 expression was increased in invasive breast cancer. CARM1 overexpression was associated with poorly characterized clinicopathologic parameters and HER2 overexpression. There were significant differences between different molecular subtypes in their relationship to CARM1 overexpression. Our results support the value of using CARM1 in prognostic stratification of breast cancer patients and its potential therapeutic implications in targeting treatment.

Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/4116338491022965.

Citing Articles

Biochemical Properties of CARM1: Impact on Western Blotting and Proteomic Studies.

Bourassa J, Paris G, Trinkle-Mulcahy L, Cote J ACS Omega. 2024; 9(38):40204-40213.

PMID: 39346878 PMC: 11425859. DOI: 10.1021/acsomega.4c06360.

Protein Arginine Methyltransferase CARM1 in Human Breast Cancer.

Bacabac M, Liu P, Xu W Endocrinology. 2024; 165(8).

PMID: 38878278 PMC: 11220664. DOI: 10.1210/endocr/bqae068.

A CARM1 Inhibitor Potently Suppresses Breast Cancer Both In Vitro and In Vivo.

Peng B, Ran T, Chen X, Ding J, Wang Z, Li W J Med Chem. 2024; 67(10):7921-7934.

PMID: 38713486 PMC: 11129188. DOI: 10.1021/acs.jmedchem.3c02315.

The emerging role of CARM1 in cancer.

Xie Z, Tian Y, Guo X, Xie N Cell Oncol (Dordr). 2024; 47(5):1503-1522.

PMID: 38619752 PMC: 11466993. DOI: 10.1007/s13402-024-00943-9.

Osteosarcoma Multi-Omics Landscape and Subtypes.

Tang S, Roberts R, Cheng L, Li L Cancers (Basel). 2023; 15(20).

PMID: 37894336 PMC: 10605601. DOI: 10.3390/cancers15204970.

References

Hong H, Kao C, Jeng M, Eble J, Koch M, Gardner T . Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer. 2004; 101(1):83-9. DOI: 10.1002/cncr.20327. View

Wong S, Goodin S . Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy. 2009; 29(8):954-65. DOI: 10.1592/phco.29.8.954. View

Al-Dhaheri M, Wu J, Skliris G, Li J, Higashimato K, Wang Y . CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells. Cancer Res. 2011; 71(6):2118-28. PMC: 3076802. DOI: 10.1158/0008-5472.CAN-10-2426. View

Jones H, Antonini N, Hart A, Peterse J, Horiot J, Collin F . Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009; 27(30):4939-47. PMC: 2799051. DOI: 10.1200/JCO.2008.21.5764. View

Higgins M, Baselga J . Targeted therapies for breast cancer. J Clin Invest. 2011; 121(10):3797-803. PMC: 3195649. DOI: 10.1172/JCI57152. View

Yadav N, Lee J, Kim J, Shen J, Hu M, Aldaz C . Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice. Proc Natl Acad Sci U S A. 2003; 100(11):6464-8. PMC: 164469. DOI: 10.1073/pnas.1232272100. View

Lahusen T, Henke R, Kagan B, Wellstein A, Riegel A . The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat. 2009; 116(2):225-37. PMC: 2975452. DOI: 10.1007/s10549-009-0405-2. View

Feng Q, He B, Jung S, Song Y, Qin J, Tsai S . Biochemical control of CARM1 enzymatic activity by phosphorylation. J Biol Chem. 2009; 284(52):36167-36174. PMC: 2794732. DOI: 10.1074/jbc.M109.065524. View

Ali S, Coombes R . Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2003; 2(2):101-12. DOI: 10.1038/nrc721. View

10.

Collins L, Marotti J, Gelber S, Cole K, Ruddy K, Kereakoglow S . Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2011; 131(3):1061-6. DOI: 10.1007/s10549-011-1872-9. View

11.

Frietze S, Lupien M, Silver P, Brown M . CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res. 2008; 68(1):301-6. DOI: 10.1158/0008-5472.CAN-07-1983. View

12.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

13.

Chen D, Ma H, Hong H, Koh S, Huang S, Schurter B . Regulation of transcription by a protein methyltransferase. Science. 1999; 284(5423):2174-7. DOI: 10.1126/science.284.5423.2174. View

14.

Urwyler O, Zhang L, Li X, Imboden H, Suter B . Tissue-dependent subcellular localization of Drosophila arginine methyl-transferase 4 (DART4), a coactivator whose overexpression affects neither viability nor differentiation. Differentiation. 2007; 75(8):757-65. DOI: 10.1111/j.1432-0436.2007.00175.x. View

15.

El Messaoudi S, Fabbrizio E, Rodriguez C, Chuchana P, Fauquier L, Cheng D . Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci U S A. 2006; 103(36):13351-6. PMC: 1569167. DOI: 10.1073/pnas.0605692103. View

16.

Bedford M, Clarke S . Protein arginine methylation in mammals: who, what, and why. Mol Cell. 2009; 33(1):1-13. PMC: 3372459. DOI: 10.1016/j.molcel.2008.12.013. View

17.

Baselga J, Swain S . Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009; 9(7):463-75. DOI: 10.1038/nrc2656. View

18.

Majumder S, Liu Y, Ford 3rd O, Mohler J, Whang Y . Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate. 2006; 66(12):1292-301. DOI: 10.1002/pros.20438. View

19.

Carascossa S, Dudek P, Cenni B, Briand P, Picard D . CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor alpha by cAMP. Genes Dev. 2010; 24(7):708-19. PMC: 2849127. DOI: 10.1101/gad.568410. View

20.

Skliris G, Leygue E, Curtis-Snell L, Watson P, Murphy L . Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer. 2006; 95(5):616-26. PMC: 2360679. DOI: 10.1038/sj.bjc.6603295. View